**Supplementary Table S4: Progression-free and overall survival calculated from Kaplan Meier plots.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|   |  |  | **no. ofpatients** | **mPFS in months** | **95% CI** | **log rank (EGFR-TKI vs. chemo)** | **log rank overall** |
| **1L PFS** | uncommon, group1 | TKI | 41 | 8.0 | 2.5 - 13.6 | **0.025** | 0.080 |
| chemo | 33 | 4.9 | 0.5 - 9.3 |  |   |
| ICI | 3 | 3.0 | n.c. |   |   |
| exon 20 ins, group 2 | TKI | 13 | 4.0 | 2.8 - 5.2 | 0.471 | 0.627 |
| chemo | 39 | 6.9 | 3.7 - 10.1 |   |   |
| ICI | 6 | 3.4 | 0.4 - 6.3 |   |   |
| very rare, group 3 | TKI | 39 | 6.7 | 5.3 - 8.2 | 0.183 | 0.417 |
| chemo | 41 | 5.5 | 2.8 - 8.1 |   |   |
| ICI | 6 | 0.9 | 0.0 - 13.2 |   |   |
|  |  |  | **no. oftreatments** | **mPFS in months** | **95% CI** | **log rank (EGFR-TKI vs. chemo)** | **log rank overall** |
| **all lines PFS** | uncommon, group1 | TKI | 79 | 6.6 | 3.8 - 9.4 | **0.003** | **0.016** |
| chemo | 55 | 4.9 | 2.5 - 7.4 |   |   |
| ICI | 11 | 3.0 | 0.2 - 5.8 |   |   |
| exon 20 ins, group 2 | TKI | 26 | 3.3 | 2.2 - 4.4 | 0.346 | 0.602 |
| chemo | 66 | 5.0 | 3.2 - 6.7 |   |   |
| ICI | 23 | 3.2 | 2.3 - 4.1 |   |   |
| very rare, group 3 | TKI | 78 | 6.7 | 4.9 - 8.6 | **0.023** | 0.074 |
| chemo | 83 | 3.5 | 1.8 - 5.1 |   |   |
| ICI | 27 | 4.3 | 0.6 - 8.4 |   |   |
|  |  |  | **no. ofpatients** | **mOS in months** | **95% CI** | **log rank (EGFR-TKI vs. chemo)** | **log rank overall** |
| **1L OS** | uncommon, group1 | TKI | 41 | 18.0 | 11.7 - 24.4 | 0.929 | 0.986 |
| chemo | 36 | 13.9 | 1.7 - 26.1 |   |   |
| ICI | 3 | 7.7 | n.c. |   |   |
| exon 20 ins, group 2 | TKI | 13 | 28.7 | 0.0 - 63.0 | 0.251 | 0.188 |
| chemo | 41 | 15.0 | 8.0 - 22.1 |   |   |
| ICI | 5 | 4.8 | 2.1 - 7.6 |   |   |
| very rare, group 3 | TKI | 38 | 20.5 | 1.7 - 39.4 | 0.128 | **<0.001** |
| chemo | 44 | 12.3 | 8.2 - 16.4 |   |   |
| ICI | 7 | 3.4 | 0.0 - 7.6 |   |   |

n.c., not calculated because of too little *n* or all cases were censored.